Summary
Forty-three of fifty-eight (74.1%) female patients with fibromyalgia completed an eight-week treatment period testing the combination of carisoprodol, paracetamol (acetaminophen) and caffeine versus placebo. Twenty-three patients received placebo and twenty active medication. In the placebo group 56.5% of the patients used additional analgesics or nonsteroidal anti-inflammatory drugs compared to only 20% in the active treatment group (p=0.015). Forty-three percent of the patients in the placebo group and none of the patients in the active treatment group used tricyclic antidepressants, anxiolytics or sedatives (p=0.0008). Active treatment gave statistically significant improvement after treatment for pain (p<0.01), for sleep quality (p<0.01) and for the general feeling of sickness (p<0.05). In the active treatment group increased pressure pain threshold after eight weeks was found at 70% of the sites measured, while the pressure pain threshold was increased at only 30% of the sites in the placebo group. In the placebo group improvement was found for the pain and sleep quality (p<0.05). This improvement may in part be due to the large amounts of extra medication in this group. Thus, the combination of carisoprodol and paracetamol (acetaminophen) and caffeine are effective in the treatment of fibromyalgia.
Similar content being viewed by others
References
Carette, S., McCain, G.A., Bell, D.A., Fam, A.G. Evaluation of amitriptyline in primary fibrositis. A double-blind controlled study. Arthritis Rheum 1986, 29, 655–659.
Goldenberg, D.L., Felson, D.T., Dinerman, H. A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis Rheum 1986, 11, 1371–1377.
Clark, S., Tindall, E., Bennet, R. A double-blind crossover study of prednisone in treatment of fibrositis. Arthritis Rheum 1984, suppl. 27, 76 D1.
Campbell, S.M., Gatter, R.A., Clark, S., Bennet, R.M. A double-blind study of cyclobenzaprine versus placebo in patients with fibrositis. Arthritis Rheum 1984, suppl. 27, 76 D3.
Editorial. To-day's drugs. Carisoprodol. Br Med J 1964, (23 May), 1364.
Gatter, R.A. Pharmacotherapeutics in fibrositis. Am J Med 1986, 81 (suppl 3 A), 63–66.
Moldofsky, H., Tullis, C., Lue, F.A., Quance, R., Davidson, J. Sleep-related myoclonus in rheumatic pain modulation disorder (fibrositis syndrome) and in excessive daytime somnolence. Psychsom Med 1984, 46, 145–151.
Smythe, H.A. Fibrositis, a disorder of pain modulation. Clin Rheum Dis 1979, 5, 823–832.
Yunus, M.A., Masi, A.T., Calabro, J.J., Miller, K.A., Feigenbaum, S.L. Primary fibromyalgia (fibrositis): Clinical study of 50 patients with matched normal controls. Semin Arthritis Rheum 1981, 11, 151–171.
The trigger point manual. In: Myofascial Pain and Dysfunction. Editors: Travel, J.G., Simons, D.G. Williams and Wilkins Baltimore, 1983.
Laska, E.M., Sunshine, A., Mueller, F., Elvers, W.B., Siegel, C., Rubin, A. Caffeine as an analgesic adjuvant. JAMA 1984, 13, 1711–1718.
Vaerøy, H., Helle, R., Førre, Ø., Kåss, E., Terenius, L. Elevated CSF levels of substance P and high incidence of Raynaud's phenomenon in patients with fibromyalgia: New features for diagnosis. Pain 1988, 32, 21–26.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Vaerøy, H., Abrahamsen, A., Førre, Ø. et al. Treatment of fibromyalgia (Fibrositis syndrome): A parallel double blind trial with carisoprodol, paracetamol and caffeïne (Somadril comp®) versus placebo. Clin Rheumatol 8, 245–250 (1989). https://doi.org/10.1007/BF02030081
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02030081